Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer reported better-than-expected second-quarter results on Tuesday, powered by strong demand for Eliquis. The drugmaker now targets $2.5 billion in additional cost cuts to restore growth. CEO Albert Bourla said, "launched and acquired products performed well." The company is also looking for a new Chief Financial Officer this month.